HUF pancreatic cancer
Clinical research
University Hospital of Fuenlabrada.
·Fuenlabrada ·

The HUF pancreatic cancer group is currently participating in the TRIPP-FFX trial: FOLFIRINOX versus OncoSil™ in addition to FOLFIRINOX for patients with locally advanced pancreatic adenocarcinoma. This is an open-label, multicenter, randomized trial of intratumoral targeted therapy of P-32 (OncoSil™) associated with FOLFIRINOX chemotherapy compared to FOLFIRINOX alone in patients with unresectable locally advanced pancreatic adenocarcinoma. The purpose of the study is to evaluate the safety and efficacy of OncoSil™ when administered in addition to standard FOLFIRINOX chemotherapy for the treatment of locally advanced pancreatic cancer.

Main publications in pancreatic cancer:

  1. Bockorny, B., Semenisty, V., Macarulla, T. et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med 26, 878-885 (2020).
  2. Manuel Hidalgo; Francesca Sarno; Laura Medina; Roberto Pazo; Ignacio Juez; Rocío García-Carbonero; Carmen Guillén-Ponce; Jaime Feliú; Carolina Alonso; Jair Tenorio_Castano; Pablo Lapunzina. Abstract CT225: A randomized trial of integrated genomics, organoids and avatar mouse models for personalized treatment of pancreatic cancer. Cancer Res (2022) 82 (12_Supplement): CT225.
  3. Hidalgo M, Garcia-Carbonero R, Lim KH, Messersmith WA, Garrido-Laguna I, Borazanci E, Lowy AM, Medina Rodriguez L, Laheru D, Salvador-Barbero B, Malumbres M, Shields DJ, Grossman JE, Huang X, Tammaro M, Martini JF, Yu Y, Kern K, Macarulla T. A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. Cancer Res Commun. 2022 Nov 2;2(11):1326-1333. 
David Gutierrez Abad

Principal Investigator

Group members

  • David Gutiérrez Abad
  • Ignacio Juez
  • Elia Martinez
  • Francesca Sarno
  • Fernando Pereira
  • María Victoria Torres

Other groups